Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of Paclitaxel-binding albumin, Cisplatin as neoadjuvant chemotherapy
in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle
invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.